Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2293590 | 0.76 | ACACB (0.46) | ACACBPPARGPPARA | |
| SCHEMBL4583470 | 0.74 | NPSR1 (0.50) | ACACBKMT2AALDH1A1 | |
| SCHEMBL21840525 | 0.74 | LDHA (0.58) | LDHAACACBSLC6A4ALDH1A1FPR2 | |
| SCHEMBL18262488 | 0.72 | LDHA (0.57) | LDHACA2SLC6A4KMT2AFPR2 | |
| SCHEMBL18262496 | 0.72 | LDHA (0.57) | LDHACA2SLC6A4KMT2AFPR2 | |
| SCHEMBL2308642 | 0.71 | LDHA (0.58) | LDHAACACBKMT2AALDH1A1FPR2 | |
| SCHEMBL18262755 | 0.71 | LDHA (0.58) | LDHAACACBKMT2AALDH1A1FPR2 | |
| SCHEMBL28558886 | 0.70 | POLB (0.59) | LDHACA2KMT2AFPR2 | |
| SCHEMBL18262548 | 0.70 | POLB (0.59) | LDHACA2KMT2AFPR2 | |
| SCHEMBL18262675 | 0.70 | LDHA (0.54) | LDHAACACBCA2SLC6A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | LDHA 843/4885ACACB 1710/4885CA2 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.